Dkk‐3 is elevated in CSF and plasma of Alzheimer’s disease patients
Authors:
Open Access
- 25 June 2009
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 110 (2) , 653-661
Abstract
Biomarkers in CSF can offer improved diagnostic accuracy for Alzheimer’s disease (AD). The present study investigated whether the glycoprotein and putative tumor suppressor Dickkopf homolog 3 (Dkk‐3) is secreted into CSF and evaluated its applicability as a diagnostic marker for AD. Using our highly specific immunoenzymometric assay, Dkk‐3 levels were measured in plasma and/or CSF of patients suffering from depression, mild cognitive impairment (MCI), or AD and compared with healthy subjects. Dkk‐3 identity was verified by western blot and matrix‐assisted laser desorption/ionization time‐of‐flight (MALDI‐TOF) mass spectrometry (MS)/MS. High concentrations of Dkk‐3 were detected in CSF compared with plasma (28.2 ± 1.3 vs. 1.22 ± 0.04 nmol/L, respectively). Consistently Dkk‐3 expression was demonstrated in neurons of the cortex and epithelial cells of the choroid plexus, the major source of CSF. Significantly increased Dkk‐3 levels in plasma and CSF were observed for AD patients compared with healthy subjects but not patients suffering from MCI or depression. In summary, our data indicate that elevated Dkk‐3 levels are specifically associated with AD and might serve as a potential non‐invasive AD biomarker in plasma.Keywords
This publication has 32 references indexed in Scilit:
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderlyAnnals of Neurology, 2009
- CSF biomarkers in frontotemporal lobar degeneration with known pathologyNeurology, 2008
- Cerebrospinal Fluid Neurochemical Phenotypes in Vascular Dementias: Original Data and Mini-ReviewDementia and Geriatric Cognitive Disorders, 2008
- Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other DementiasDementia and Geriatric Cognitive Disorders, 2005
- En route to early diagnosis of Alzheimer's disease – are we there yet?Trends in Biotechnology, 2005
- CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatmentExpert Review of Molecular Diagnostics, 2005
- Diagnosis and treatment of Alzheimer’s diseaseNeurology, 2005
- Down‐regulation of Dickkopf 3, a regulator of the Wnt signalling pathway, in elderly schizophrenic subjectsJournal of Neurochemistry, 2005
- Characterisation of the Wnt antagonists and their response to conditionally activated Wnt signalling in the developing mouse forebrainDevelopmental Brain Research, 2004
- CSF biomarkers for mild cognitive impairmentJournal of Internal Medicine, 2004